Canine Anti-ICOS Antibody for the Treatment of Chronic GVHD

Monoclonal antibody against ICOS significantly increase survival of dogs with chronic GVHD.

  • Stage: Pre-clinical in vivo
  • Type: Research Tool, Therapeutic
  • Categories: Hybridoma / Antibody

Technology Overview

In canines, lymphoma comprises up to 24% of all canine cancers. Hematopoietic cell transplantation (HCT) is increasing in popularity as a treatment for lymphoma, however there is a significant risk of graft-versus-host disease (GVHD) as a result. The Storb Lab developed a model system for producing chronic GVHD in canines given HCT and have identified an anti-canine ICOS monoclonal antibody which significantly extends canine survival. Progression of chronic GVHD in canines was halted or even completely eliminated after treatment with anti-ICOS. This antibody can be used as a therapeutic for GVHD treatment in canines.


  • Canine GVHD therapeutic
  • Research tool

Investigator Overview

Rainer Storb, MD
Tech ID: 16-066
Asset 1